A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH09-08-0525
Issue:2010: 103/5 (May) pp. 875–1108
Pages:968-975

A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care

G. Mazzaglia (1), A. Filippi (2), M. Alacqua (3), W. Cowell (4), A. Shakespeare (4), L. G. Mantovani (5), C. Bianchi (6), C. Cricelli (2)

(1) Health Search, Italian College of General Practitioners, Florence, Italy; (2) Italian College of General Practitioners, Florence, Italy; (3) IRCCS Centro Neurolesi ‘Bonino-Pulejo’, Messina, Italy; (4) Bayer HealthCare, Uxbridge, UK; (5) CIRFF – Center of Pharmacoeconomics, Federico II University of Naples, Naples, Italy; (6) Bayer HealthCare, Milan, Italy

Summary

The aims of this study were to investigate trends in the incidence of diagnosed atrial fibrillation (AF), and to identify factors associated with the prescription of antithrombotics (ATs) and to identify the persistence of patients with oral anticoagulant (OAC) treatment in primary care. Data were obtained from 400 Italian primary care physicians providing information to the Health Search/Thales Database from 2001 to 2004. The age-standardised incidence of AF was: 3.9–3.0 cases, and 3.6–3.0 cases per 1,000 person-years in males and females, respectively. During the study period, 2,016 (37.2%) patients had no prescription, 1,663 (30.7%) were prescribed an antiplatelet (AP) agent, 1,440 (26.6%) were prescribed an OAC and 301 (5.5%) had both prescriptions. The date of diagnosis (p = 0.0001) affected the likelihood of receiving an OAC. AP, but not OAC, use significantly increased with a worsening stroke risk profile using the CHADS2 risk score. Older age increased the probability (p < 0.0001) of receiving an AP, but not an OAC. Approximately 42% and 24% of patients persisted with OAC treatment at one and two years, respectively, the remainder interrupted or discontinued their treatment. Underuse and discontinuation of OAC treatment is common in incident AF patients. Risk stratification only partially influences AT management.

Keywords

incidence, Atrial fibrillation, treatment, risk stratification, antithrombotics, oral anticoagulant, therapeutic persistence

DOI

http://dx.doi.org/10.1160/TH09-08-0525

You may also be interested in...

1.

S. Kääb1, U. Schotten2, D. Dobrev3, P. Kirchhof4, U. Ravens3, A. Goette5 für den Bereich Pathophysiologie des BMBF Kompetenznetz Vorhofflimmern (www.kompetenznetz-vorhofflimmern. de).

Die Medizinische Welt 2007 58 4: 131-134

2.

M. V. Huisman (1), G. Y. H. Lip (2), H.-C. Diener (3), M. Brueckmann (4), J. van Ryn (5), A. Clemens (4)

Thrombosis and Haemostasis 2012 107 5: 838-847

http://dx.doi.org/10.1160/TH11-10-0718

3.

See also Editorial by Apostolakis, Lip

A. M. Gallagher (1), E. Setakis (1), J. M. Plumb (2), A. Clemens (2), T.-P. van Staa (1, 3)

Thrombosis and Haemostasis 2011 106 5: 968-977

http://dx.doi.org/10.1160/TH11-05-0353



Articles

You've 999 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...